9 articles in this category
In 2022, a well-funded longevity startup paused its first human trial. Not because of safety data — safety looked fine. Because an internal memo, leak...
Sometime in the next decade, a drug cocktail could add ten years to human median lifespan. That is not science fiction—it is the stated goal of three ...
You eat clean. You exercise. You take the supplements. But what if your cells are still running on a damaged script written decades before you were bo...
Every week, another longevity app tells me my 'biological age.' Usually it's a number pulled from a blood test or a methylation panel. But whose biolo...
Imagine a world where 90-year-olds have the biological age of 40. Clinical trials for senolytic drugs are clearing age-related diseases at rates no on...
Your company will pivot. Maybe not this quarter, but soon. And when it does, most frameworks — the ones you spent months building — will shatter. They...
Imagine you are builded a longevity setup — a stack of intervening, biomarkers, and protocols — but the clock is ticking. Your investors want a go/no-...
Planned obsolescence is not an accident—it's a concept choice incentivized by the faulty metrics. For decades, engineers have measured reliability usi...
You have a compound that extends mouse lifespan by 15%. Your cells look younger under the microscope. Investors are excited. But when you scale to hum...